FDA’s OGD Takes Fight To COVID-19 With Half-Century Of Approvals
Six-Dozen First Generics Approved Last Year Including $3.3bn Tecfidera
Executive Summary
The sixth annual report of the FDA’s Office of Generic Drugs covered a year dominated by the novel coronavirus pandemic – although first-time generic approvals and record levels of communication also featured prominently.
You may also be interested in...
Slayback Exclusivity On Taytulla Does Not Bar Rival ANDA Product
Slayback Pharma has now launched its Merzee generic version of Allergan’s Taytulla oral contraceptive with a CGT designation, several months after Xiromed moved first.
US FDA Recalibrates Office Of Generic Drugs
As part of a wider overhaul of the FDA’s Center for Drug Evaluation and Research, the agency is reorganizing its Office of Generic Drugs, including adding a new Office of Safety and Clinical Evaluation within the OGD.
Amphastar Has First US Glucagon Rival
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests: